Appointing an EU Legal Representative for your clinical trials is now a legal requirement for any sponsor established outside the European Union wishing to conduct a clinical study within the EU. Even for European sponsors, outsourcing this role to a specialized regulatory expert can make the difference between a smooth approval process and months of unnecessary delays. Here’s what you need to know.
EU Legal Representative for Clinical Trials: Definition and Legal Framework
Since the entry into force of Regulation (EU) No. 536/2014 on medicinal product clinical trials (applicable since 31 January 2022) and Regulation (EU) 2017/745 (MDR) on medical devices, sponsors established outside the European Union must appoint a Legal Representative established within the EU whenever they conduct clinical trials or clinical investigations in Europe.
Acting on behalf of the sponsor, the Representative assumes the regulatory responsibilities defined by European legislation and serves as the official contact for competent authorities, including the French National Agency for Medicines and Health Products Safety (ANSM) and, for medicinal product clinical trials in France, the French Ethics Committees (CPP).
In practice, the EU Legal Representative is the officially recognised point of contact for European regulators. This representative is responsible for submitting the clinical trial application through the Clinical Trials Information System (CTIS), responding to requests for additional information, and ensuring ongoing regulatory compliance throughout the lifecycle of the study.
For more information on the European Clinical Trials Regulation, visit the European Commission website:
https://health.ec.europa.eu/medicinal-products/clinical-trials_en
Who Must Appoint an EU Legal Representative?
The legal requirement is straightforward: any sponsor whose registered office is located outside the European Union must appoint an EU Legal Representative before initiating clinical trials within the EU.
This requirement notably applies to:
- US, Asian or Swiss pharmaceutical companies planning to include European investigational sites;
- Non-EU biotech start-ups entering the clinical development phase;
- Academic sponsors from third countries conducting research involving European participants.
Beyond this legal obligation, an increasing number of European sponsors also choose to work with a specialised EU Legal Representative to secure their CTIS submissions and efficiently manage the growing complexity of multinational regulatory requirements.
What Are the Responsibilities of an EU Legal Representative?
His role extends far beyond providing a legal address. It covers every stage of the clinical trial lifecycle.
Regulatory Submission and Compliance
The representative is responsible for:
- submitting the initial application through CTIS;
- managing substantial modifications;
- ensuring timely publication of trial results in accordance with European regulations.
Communication with Competent Authorities
Authorities such as the ANSM, the European Medicines Agency (EMA) and national ethics committees communicate directly with him regarding all regulatory matters related to the clinical trial.
Legal Responsibility
In the event of non-compliance with ICH Good Clinical Practice (ICH-GCP) or failures in safety reporting, the Representative assumes the legal responsibilities assigned under European legislation.
Continuous Safety Oversight
The representative also oversees the reporting of Serious Adverse Events (SAEs) and ensures that safety information is submitted to competent authorities within the required regulatory timelines.
Why Choose an Expert Representative Instead of an Administrative Provider?
Several companies offer low-cost Legal Representative services for clinical trials, limiting their role to providing a registered European address. While this may appear attractive from a financial perspective, it can expose sponsors to significant regulatory risks.
European authorities—particularly the French National Agency for Medicines and Health Products Safety (ANSM)—expect the appointed representative to possess genuine regulatory expertise and a thorough understanding of European clinical trial requirements. An EU Legal Representative without practical experience in clinical research may struggle to answer regulators’ questions, manage substantial amendments, or react appropriately when unexpected issues arise during a study.
Choosing an experienced regulatory partner offers several key advantages:
- Optimised CTIS submissions that reduce the risk of requests for additional information;
- Rapid and informed communication with European competent authorities throughout the study;
- Comprehensive regulatory support, including monitoring, pharmacovigilance, medical writing, and clinical operations when required.
Ultimately, selecting the right Representative is not simply about meeting a legal obligation—it is about protecting your development timelines, reducing regulatory risk, and ensuring the success of your European clinical trials.
To learn more about CTIS and the European clinical trial process, visit the European Medicines Agency:
https://www.ema.europa.eu/en/human-regulatory-overview/research-development/clinical-trials-human-medicines/clinical-trials-information-system
BluePharm: Your Trusted Representative for Clinical Trials
BluePharm provides Representative services for medicinal product clinical trials and medical device clinical investigations conducted throughout the European Union.
Founded in 2017, BluePharm is a full-service Contract Research Organization (CRO) combining regulatory expertise, operational excellence, and extensive experience with the Clinical Trials Information System (CTIS). Our multidisciplinary team supports sponsors at every stage of their development programmes, ensuring compliance with European regulations while facilitating efficient interactions with regulatory authorities.
Whether you are a pharmaceutical company, biotechnology start-up, medical device manufacturer or academic sponsor, we help you secure your European submissions and maintain regulatory compliance throughout your clinical trials.
If your organisation is based outside the European Union—or if you simply wish to strengthen your European regulatory strategy—our specialists are ready to support you from the earliest stages of study planning.
Learn more about European clinical trial requirements on the European Commission website:
https://health.ec.europa.eu/medicinal-products/clinical-trials_en
Planning a clinical trial in Europe?
Contact BluePharm today to discuss your project and discover how our experienced team can support your European clinical development from study design through regulatory submission and beyond.
